8-K: Aquestive Therapeutics' Anaphylm NDA Accepted by FDA, PDUFA Date Set for January 2026

Aquestive Therapeutics, Inc. announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for Anaphylm, an orally delivered epinephrine option for severe allergic reactions, setting a Prescription Drug User Fee Act (PDUFA) target action date of January 31, 2026.

Summary

• The U.S. Food and Drug Administration (FDA) has accepted Aquestive Therapeutics' New Drug Application (NDA) for Anaphylm.
• Anaphylm is intended for the treatment of Type 1 allergic reactions, including anaphylaxis.
• The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 31, 2026, for Anaphylm.
• If approved, Anaphylm would be the first and only orally delivered epinephrine option for severe allergic reactions in the United States.
• The FDA reiterated that it may decide to conduct an Advisory Committee meeting for the approval of Anaphylm.
• Anaphylm is designed as a device-free, orally delivered sublingual film, similar in size to a postage stamp, thinner than a credit card, and requires no special storage or water for administration.

Sentiment

Score: 8

Explanation: The FDA's acceptance of the NDA and setting of a PDUFA date for Anaphylm is a major positive development, indicating significant progress towards commercialization of a potentially first-in-class, orally delivered epinephrine product that addresses significant unmet patient needs. This reduces regulatory risk and provides a clear path forward.

Positives

• FDA acceptance of the New Drug Application (NDA) for Anaphylm, a critical regulatory milestone.
• Assignment of a PDUFA target action date of January 31, 2026, providing a clear timeline for potential approval.
• Anaphylm, if approved, would be the first and only orally delivered epinephrine option, addressing a significant unmet need in anaphylaxis treatment.
• The product's design as a device-free, sublingual film (thinner than a credit card, no special storage) aims to overcome key patient barriers like fear of needles and inconvenience of carrying bulky devices.
• Clinical data supports Anaphylm's ability to rapidly deliver epinephrine absorption orally.
• The potential for Anaphylm to improve patient adherence to carrying and using life-saving epinephrine due to its user-friendly design.

Risks

• Potential for delays or changes to the timing, cost, and success of product development activities and clinical trials for Anaphylm and AQST-108.
• Risk of delays in the regulatory approval process through the FDA or failure to receive FDA approval at all for product candidates, including Anaphylm and AQST-108.
• Risk of the Company's inability to generate sufficient clinical data for approval, including for pharmacokinetic and pharmacodynamic comparability submission for FDA approval of Anaphylm.
• Risk of the Company's inability to address FDA's comments on clinical trials and other concerns identified in FDA's Type C meeting minutes and filing review letter for Anaphylm, potentially requiring additional clinical studies.
• Risk that the FDA may require an Advisory Committee meeting for Anaphylm approval, and the Company may not be able to address any concerns raised by such committee or the FDA.
• Risk of the success of competing products, including generics.
• Risks and uncertainties inherent in commercializing a new product, including technology, financial, market, implementation risks, and regulatory limitations.
• Risk of insufficient capital and cash resources, including access to debt and equity financing, to satisfy liquidity and cash requirements and fund commercialization activities.
• Risk of eroding market share for Suboxone, which accounts for a substantial part of current operating revenue.
• Risk of default of debt instruments.
• Risks related to the outsourcing of certain sales, marketing, and other operational functions to third parties.
• Risk of the rate and degree of market acceptance in the U.S. of Anaphylm and other product candidates, if approved.
• Risk of compliance with all FDA and other governmental and customer requirements for manufacturing facilities.
• Risks associated with intellectual property rights and infringement claims relating to products, including the timely issuance of patents for Anaphylm.
• Risk of unexpected patent developments.
• Risk of legislation and regulatory actions and changes in laws or regulations affecting the business, including product pricing, reimbursement, or access.
• Risk of loss of significant customers.
• Risks related to claims and legal proceedings against Aquestive, including patent infringement, securities, business torts, investigative, product safety or efficacy, and antitrust litigation matters.
• Risk of product recalls and withdrawals.
• Risks related to any disruptions in information technology networks and systems, including the impact of cybersecurity attacks.
• Risk of increased cybersecurity attacks and data accessibility disruptions due to remote working arrangements.
• Risk of adverse developments affecting the financial services industry.
• Risks related to inflation and rising interest rates.
• Risks related to the impact of the COVID-19 global pandemic and other pandemic diseases on the business.
• Risks and uncertainties related to general economic, political (including the Ukraine and Israel wars and other acts of war and terrorism), business, industry, regulatory, financial, and market conditions.
• Risks related to uncertainties about U.S. government initiatives and their impact on the business, including imposition of tariffs and other trade restrictions.

Future Outlook

Aquestive Therapeutics anticipates potential FDA approval for Anaphylm by January 31, 2026, which would establish it as the first and only orally delivered epinephrine option for severe allergic reactions in the U.S. The company acknowledges the possibility of an FDA Advisory Committee meeting prior to approval. Additionally, Aquestive is advancing an earlier stage epinephrine prodrug topical gel product candidate, AQST-108, for potential dermatology conditions.

Management Comments

• "We designed Anaphylm to fit seamlessly into the patients daily life. Its thinner than a credit card and requires no special storage, so patients can keep it in their phone case, wallet, or pocket – Anaphylm can go everywhere you go, without the bulk of even the smallest FDA-approved device for this patient population." Dan Barber, President and Chief Executive Officer of Aquestive.
• "Our clinical data demonstrates Anaphylms ability to rapidly deliver epinephrine absorption orally." Dan Barber, President and Chief Executive Officer of Aquestive.
• "With the FDAs acceptance of our NDA, were one step closer to getting this life-saving innovation in the hands of the patients and caregivers who need it most." Dan Barber, President and Chief Executive Officer of Aquestive.
• "Anaphylaxis is an unpredictable, severe allergic reaction that can be life-threatening within minutes. While epinephrine remains the only FDA-approved first-line treatment, too many at-risk individuals don't carry it consistently or hesitate to use it when seconds count." Dr. David Stukus, M.D., Professor of Clinical Pediatrics and Director of the Food Allergy Treatment Center at Nationwide Childrens Hospital and The Ohio State University College of Medicine.
• "The reality is stark: epinephrine can only save lives if people have it available and feel confident using it immediately. This potential drug product addresses the two biggest barriers we hear from patients – fear of administration and the inconvenience of carrying bulky devices. An oral, no-needle approach could be transformative for anaphylaxis care." Dr. David Stukus, M.D.

Industry Context

The current standard of care for anaphylaxis treatment primarily involves injectable epinephrine devices. Anaphylm, if approved, would introduce a novel, orally delivered, device-free alternative, potentially revolutionizing patient adherence and immediate treatment by addressing common barriers such as the fear of needles and the inconvenience of carrying bulky auto-injectors. This could significantly expand the accessibility and consistent use of life-saving epinephrine.

Comparison to Industry Standards

• Anaphylm is positioned as the first and only orally delivered epinephrine option, contrasting with the current market dominated by needle-based epinephrine products (e.g., auto-injectors).
• It is a device-free sublingual film, eliminating the need for bulky devices associated with existing FDA-approved epinephrine treatments.
• Its compact size (similar to a postage stamp, thinner than a credit card) and light weight (less than an ounce) offer superior portability compared to even the smallest FDA-approved devices for this patient population.
• Administration requires no water or swallowing, simplifying use in emergency situations, unlike some oral medications.
• The packaging is designed to withstand weather excursions (e.g., rain, sunlight), enhancing its durability and reliability for daily carry.

Stakeholder Impact

• Shareholders: Highly positive impact due to significant progress towards commercialization of a potentially high-value, market-disrupting product, reducing regulatory uncertainty and increasing future revenue potential.
• Patients: Potential for a more convenient, less intimidating, and more consistently carried epinephrine option for severe allergic reactions, which could lead to improved adherence and better emergency outcomes.
• Caregivers: Easier administration and improved peace of mind regarding emergency treatment for individuals under their care, particularly children or those with needle phobias.
• Healthcare Providers: A novel, patient-friendly treatment option to recommend, potentially improving patient compliance with carrying life-saving medication and addressing current barriers to use.
• Competitors: May face increased competition from a new, differentiated product that addresses existing market gaps in convenience and administration.

Next Steps

• FDA's continued review of the Anaphylm New Drug Application (NDA).
• Potential FDA Advisory Committee meeting for Anaphylm approval.
• FDA decision on Anaphylm approval by the PDUFA target action date of January 31, 2026.
• If approved, Aquestive Therapeutics will proceed with commercialization activities for Anaphylm.
• Continued advancement of the earlier stage epinephrine prodrug topical gel product candidate, AQST-108.

Key Dates

Recommendation

Keywords

Anaphylm, epinephrine, sublingual film, FDA, NDA, PDUFA, anaphylaxis, allergic reactions, Aquestive Therapeutics, AQST, pharmaceutical, drug approval, oral delivery, emergency medicine, Type 1 allergic reactions